November 5, 2026, Shanghai - The 9th China International Import Expo opened in Shanghai. As a "Quality Student" that has participated in the exhibition for nine consecutive years, Bayer once again showed up with its three business divisions: prescription drugs (and imaging diagnostics), consumer health products and crop sciences, focusing on presenting global innovation results and the latest local practices in the two major fields of medical health and modern agriculture. At this CIIE, Bayer has "dual exhibitions" in the medical equipment and pharmaceutical and health care exhibition area A3-03 in Hall 1.1 and the agricultural and food products exhibition area B3-02 in Hall 8.1, bringing nearly 30 first exhibition debuts, covering multiple directions such as disease treatment and accurate diagnosis, daily health management, and agricultural quality and efficiency improvement. Relying on the CIIE as an open window, Bayer not only accelerates the introduction of global achievements into China, but also continues to promote the integration of Chinese needs and local wisdom into the global R&D network, connecting China and the world through life science innovation.
Bayer participates in CIIE for ninth consecutive time
Bill Anderson, Chairman of the Board of Management of Bayer AG Anderson said: "For Bayer, the CIIE is not just an exhibition, but an important platform for us and partners from all walks of life to come together, exchange innovations, establish cooperation and create real value. The world today faces a series of common challenges: from improving the health of a growing and aging population to producing enough food in a responsible way. No company or country can meet these challenges alone. Only openness, collaboration and innovation can continue to promote progress. The CIIE brings together people from all walks of life and around the world. Partners make this possible. As a multinational company with a history of more than 160 years, Bayer’s mission is very clear: ‘Share health and eliminate hunger’. We look forward to deepening cooperation with all partners in the innovation ecosystem and combining Bayer’s global capabilities with China’s roots. Connect with local wisdom to build a healthier and more resilient future. Next year, Bayer will celebrate its 145th anniversary in China, which is of great significance to us. We are deeply proud to be among the few companies that have long participated in and witnessed China's development, and we look forward to continuing to move forward together. "
Bill Anderson, Chairman of the Board of Management of Bayer AG
8 major innovative products and new indications debuted at the Expo, accelerating global medical innovation to benefit Chinese patients
As the construction of a healthy China continues to advance, the accelerated availability of innovative drugs and advanced diagnosis and treatment technologies provides more possibilities to meet the growing health needs of patients. As one of the first important multinational pharmaceutical companies to achieve simultaneous research and development and simultaneous registration of new drugs around the world, Bayer continues to increase investment in innovation in China and accelerates the entry of global innovation results into China through the CIIE.
At this CIIE, Bayer’s Prescription Drug Division focused on displaying innovative results in key areas such as cardiovascular and cerebrovascular diseases, tumors, nervous system, ophthalmology, women’s health, and imaging diagnosis. Eight major innovative products and new indications for prescription drugs and imaging diagnosis made their “CIIE debut”, demonstrating Bayer’s continuous layout from innovative drug research and development to local production and supply.
Bayer prescription drug booth at the 9th China International Import Expo
The most anticipated “CIIE babies” this year are Shuhuabo (Ashuxen tablets) and Hersinox (Sevacitinib tablets), which were approved just before the opening of the CIIE. Two innovative products were unveiled at the CIIE booth for the first time.
On October 26, the National Medical Products Administration (NMPA) approved the world's first-in-class activated coagulation factor XI (FXIa) inhibitor Shuhuabo (Ashuxon Tablets) to reduce the risk of stroke in adult patients with ischemic stroke or high-risk transient ischemic attack (TIA), excluding patients with cardioembolic stroke. The marketing application for Bayer's Shuhuabo (Ashuxen Tablets) was granted priority review status. It took about half a year from acceptance to approval, allowing this global innovation to reach Chinese patients at one of the fastest speeds. Shuhuabo has also become the latest example of Bayer taking advantage of China's constantly accelerating review and approval environment for innovative drugs to accelerate global innovation to benefit Chinese patients.
On November 4, the State Food and Drug Administration approved the new targeted treatment drug for lung cancer Hercinna (sevacitinib tablets) as a single agent for the treatment of adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations in HER2 (ERBB2). Following its previous approval in China for treatment-experienced patients, this approval for all indications further expands the clinical application of Hersinox in China and promotes the precision treatment of HER2-mutated non-small cell lung cancer to an earlier stage of treatment.
The CIIE continues to witness Bayer’s innovative therapies expanding the boundaries of patient benefit. After Keshenda (fenelidone tablets) was approved for use in adult patients with chronic kidney disease related to type 2 diabetes in China in 2022, in May 2026, it was newly indicated for use in adult patients with heart failure with left ventricular ejection fraction (LVEF) ≥40%. In July this year, its application for a new indication for the treatment of non-diabetic chronic kidney disease was also submitted in China. In the future, the CIIE will continue to witness that this innovative therapy brings new treatment hope to more patients with chronic diseases.
In addition, Nobego (darostamide tablets) made its first CIIE presentation after the third indication was approved. Its combination with androgen deprivation therapy was approved for the treatment of patients with metastatic hormone-sensitive prostate cancer. It can be used regardless of whether they receive docetaxel chemotherapy. The marketing application for Alea 8mg for the treatment of macular edema secondary to retinal occlusion (RVO) has been officially accepted by the Drug Evaluation Center of the State Drug Administration, and a marketing application for the treatment of patients with diabetic macular edema (DME) will soon be submitted. This is also its first appearance at the CIIE after submitting new indications.
Precise diagnosis and treatment cannot be separated from the support of advanced imaging technology. At this CIIE, Bayer also showcased a number of its latest innovations in the field of imaging diagnosis. Among them, Gadoquinotrolan Injection was publicly displayed for the first time in China. Its marketing application has been accepted by the Drug Evaluation Center of the China National Medical Products Administration. It is intended to be used for contrast enhancement of magnetic resonance imaging (MRI) in adults and children of all ages (including newborns). In addition, the MEDRAD Mark7 Arterion high-pressure contrast injection system, which obtained the domestic medical device registration certificate in April 2026, made its first appearance at the CIIE after localization, demonstrating Bayer's latest progress in further promoting the localized production and supply capacity building of high-end imaging equipment.
Gadolinium Injection has its first exhibition in China at this CIIE
7 models were unveiled for the first time in the world, in line with the upgrade of healthy consumption, integrating scientific innovation into daily health management
As public health awareness continues to increase, people's attention to health is further extending to daily health management throughout the life cycle, and the public's demand for high-quality, personalized, and convenient health products and services continues to grow. Facing this trend, Bayer Health Consumer Products Division continues to start from consumer needs, expand self-health management solutions with scientific innovation, and rely on the "industry-university-research" collaborative innovation network built by the China Innovation Cooperation Center (CCIP) to promote the accelerated transformation of scientific research results into health solutions that consumers can perceive, obtain, and benefit from.
At this CIIE, a series of innovative products built around the segmented health needs of Chinese consumers were unveiled, including 7 world premieres and 4 “CIIE babies”.
Bayer Health Consumer Products Booth at the 9th China International Import Expo
The world's first exhibition of Kangwang Youth Selenium Disulfide Shampoo comes from Kangwang, a professional scalp care brand owned by Bayer for 30 years. Based on the classic selenium disulfide anti-dandruff formula, it is customized and upgraded specifically for the characteristics of Chinese teenagers, such as excessive oil in adolescence. It uses 0.5% pure selenium disulfide as the core, compounded with soothing and nourishing ingredients, anti-dandruff source, oil purification, and barrier protection three-dimensional conditioning to scientifically stabilize the scalp microecology and provide professional daily scalp care solutions for teenagers. In addition, the "CIIE Baby" - an upgraded version of Kangwang Selenium Disulfide Anti-dandruff and Oil Control Shampoo was also unveiled at the CIIE. It uses 1% selenium disulfide to professionally remove dandruff and control oil, and long-term protection of the scalp's freshness.
In the field of skin care for infants and young children, two "CIIE Babies" - Beilexin B5 Essence Moisturizer and Beilexin B5 Essence Hydration Series also appeared at the CIIE. Belexin B5 Essence Moisturizer is specially developed for special skin babies. It selects the brand's core active ingredients B5 panthenol, bionic vernix, etc., which can quickly relieve itching, reduce redness and strengthen the baby's skin barrier. The world's first B5 essence hydrogel series includes facial hydrogel cream and micro-gel gel that can be used all over the body. It has a dense smoothie texture that melts on the skin. It is specially customized for baby skin in summer. The brand's core active ingredient B5 panthenol is selected to quickly relieve sunburn, cool down and moisturize, and strengthen the baby's skin barrier.
From scalp health and daily skin care to health management in different life stages and life scenarios, Bayer continues to respond to consumers' diverse self-health management needs with scientific innovation. Also on display for the first time in the world at this CIIE are Little Elevit Children’s Immunity Powder, Elevit Mom Liquid Calcium, as well as One A Day Liquid Glucosamine Calcium, One A Day Women’s Time Tablets Pro and One A Day Lutein Eye Care Capsules, covering areas such as maternal and infant health and nutritional supplements, further enriching consumers’ options for active health management.
8 models debuting in China and 6 CIIE debuts, using agricultural innovation to help food security
Promoting agricultural modernization and high-quality development is inseparable from the continuous empowerment of scientific and technological innovation. Bayer CropScience, which has been rooted in China for more than 60 years, continues to combine global innovation resources with the actual needs of China's agriculture, and contributes to my country's food security through innovative results in the three major business areas of crop protection, corn seeds and vegetable seeds. At this CIIE, Bayer CropScience exhibited a total of 8 “first-in-China” products and 6 “first-ever CIIE products”.
Bayer CropScience booth at the 9th China International Import Expo
Focusing on the needs of crop nutrition and stress resistance, Dela, a crop health brand officially launched at the 2025 CIIE, this year brought the "CIIE Baby" Dela Amino Acid Magnesium. As Bayer's new generation of biostimulant product, Delai Amino Acid Magnesium is rich in 19 kinds of free L-amino acids, and synergizes with active magnesium to provide more efficient and precise nutritional support for the key growth stages of crops. From brand launch to the launch of new family products, it also further reflects the "spillover effect" of the CIIE platform in promoting the continuous implementation of innovation.
Two new generation seed coating agents from Bayer, Ogood and Fengkeqi, newly launched this year, also had their first exhibition at the CIIE. The two new products focus on the seedling management needs of corn, peanuts and wheat, moving the focus of pest and disease prevention and control further forward. Both have been verified by more than 200 local trials and have demonstrated stable performance and application value in different regions and planting conditions.
Improved seeds are also an important basis for food security. At this CIIE, Bayer's corn seed brand Dika launched eight new corn varieties in China, catering to the different planting needs of the Northeast, Northwest and Huang-Huai-Hai production areas, with a richer variety selection to respond to farmers' expectations for high yield, stress resistance, disease resistance, lodging resistance and high grain quality varieties. Bayer's vegetable seed brands Sennis and Deut also exhibited a variety of delicious varieties covering tomatoes, sweet corn, bell peppers, onions, cucumbers, broccoli and other categories. They also debuted a new cherry tomato variety Starlisher (DRTC8103) for cluster harvesting to meet the differentiated needs of growers and consumers and connect the field and the table with innovation.
Innovation is also extending from products to agricultural services and knowledge empowerment. The Dika Learning Center, which integrates field experiment demonstrations, technical training and knowledge dissemination, made its debut at the CIIE. At the same time, the Bayer Crop Science e-commerce flagship store also participated in the exhibition for the first time, extending professional agricultural solutions to more application scenarios through Tmall, JD.com and other channels.
Connecting China and the world with open innovation, CIIE platform releases the value of two-way innovation
During the nine-year CIIE, Bayer continues to use this open window to connect global resources and Chinese opportunities: on the one hand, it accelerates the introduction of global R&D results and solutions into China; on the other hand, it also allows the practical results, local wisdom and cooperation models derived from China's needs to move to a broader stage, forming a two-way flow of innovation cycle.
During this CIIE, Bayer will hold dozens of signing cooperation, achievement release and dialogue exchange activities at the two major booths, bringing together government agencies, medical and scientific research institutions, industry associations and industry partners, making the CIIE booth a platform for interconnection between China's innovation ecology and the global cooperation network. Among them, the Prescription Drugs Division will deepen cooperation around clinical research, achievement transformation, grassroots medical capacity building and major disease prevention and treatment, and promote the integration of experience derived from China's clinical practice and scientific research exploration into global research and development; the Health Consumer Products Division will focus on self-health management, scientific evidence-based and industrial collaboration, and promote Chinese consumer insights, local R&D results and cooperation models to a broader market through industry forums, joint laboratories, cooperation signings and new product releases, and use Chinese wisdom to contribute value to global health development.
Facing the future, Bayer will continue to be based in China and connect the world, respond to the continuous development needs of China's medical health and modern agriculture with its innovation capabilities in the field of life sciences, continue to deepen local innovation, open cooperation and industrial collaboration, promote more innovations from the exhibition stand to the market, from scientific research to application, from products to real life, and jointly create long-term value with the Chinese market and partners.
